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Abstract 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive 
degeneration of motoneurons, which is preceded by loss of neuromuscular connections in a “dying 
back” process. Neuregulin-1 (Nrg1) is a neurotrophic factor essential for the development and 
maintenance of neuromuscular junctions, and Nrg1 receptor ErbB4 loss-of-function mutations have 
been reported as causative for ALS. Our main goal was to investigate the role of Nrg1 type I (Nrg1-
I) in SOD1G93A mice muscles. We overexpressed Nrg1-I by means of an adeno-associated viral 
(AAV) vector, and investigated its effect by means of neurophysiological techniques assessing 
neuromuscular function, as well as molecular approaches (RT-PCR, western blot, 
immunohistochemetry, ELISA) to determine the mechanisms underlying Nrg1-I action. AAV-
Nrg1-I intramuscular administration promoted motor axon collateral sprouting by acting on 
terminal Schwann cells, preventing denervation of the injected muscles through Akt and ERK1/2 
pathways. We further used a model of muscle partial denervation by transecting the L4 spinal 
nerve. AAV-Nrg1-I intramuscular injection enhanced muscle reinnervation by collateral sprouting, 
whereas administration of lapatinib (ErbB receptor inhibitor) completely blocked it. We 
demonstrated that Nrg1-I plays a crucial role in the collateral reinnervation process, opening a new 
window for developing novel ALS therapies for functional recovery rather than preservation. 
 
Keywords: neuregulin-1, amyotrophic lateral sclerosis, neuromuscular junction, motoneuron, 
collateral sprouting. 
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Introduction 
ALS is a progressive degenerative disease selectively affecting motoneurons (Kiernan et al., 2011). 
Approximately 10% of patients have familial forms, caused by mutations in a variety of genes, the 
most prevalent involving the superoxide dismutase 1 (sod1) gene and hexanucleotide repeat 
expansions in chromosome-9 open reading frame 72 (C9ORF72) (Andersen and Al-Chalabi, 2011; 
Turner et al., 2013). Although C9ORF72 gene mutations are reported in a higher proportion of ALS 
and ALS-frontotemporal lobar degeneration patients (DeJesus-Hernandez et al., 2011; Renton et al., 
2011), SOD1-based models are still the most used tool for basic and preclinical studies. The most 
widely used ALS model is a transgenic mouse over-expressing the human mutated form of the 
SOD1 gene with a glycine to alanine conversion at the 93rd amino acid (Gurney et al., 1994; Ripps 
et al., 1995), which recapitulates the most relevant clinical and histopathological features of both 
familial and sporadic ALS (Ripps et al., 1995; Mancuso et al., 2011a; 2011b). High copy SOD1G93A 
transgenic mice develop rapidly progressive motoneuron loss, with locomotor deficits from 12-13 
weeks of age, hindlimb weakness and muscle atrophy, culminating in paralysis and death between 
ages 16 and 19 weeks (Ripps et al., 1995; Mancuso et al., 2011a; 2011b). Alterations in SOD1 
protein have also been found in sporadic ALS patients (Bosco et al., 2010), and accumulation of 
wild-type SOD1 was reported to produce ALS in mice (Graffmo et al., 2013). 
The death of motoneurons in ALS is preceded by failure of neuromuscular junctions (NMJs) 
and axonal retraction (Azzouz et al., 1997; Fischer et al., 2004; Mancuso et al., 2011b; Fischer et 
al., 2012), which seem dependent upon the interaction of motor axons with accompanying terminal 
Schwann cells and skeletal muscle fibers. Axonal sprouting is a natural mechanism attempting to 
compensate muscle denervation in motoneuron diseases and after nerve trauma (Tam and Gordon, 
2003a). Intact motoneurons expand the size of their motor units to reinnervate denervated end-
plates within the same muscle, enabling to compensate for the loss of functional motor units and 
recover muscle strength. Motor unit enlargement by axonal sprouting is restricted even under 
normal conditions to a limit of 3–5 fold, thus compensating for loss of up to 85% of the total muscle 
function (Trojan et al., 1991; Tam and Gordon, 2003b). Although collateral sprouting has been 
described to occur during ALS disease process (Frey et al., 2000), it is reduced compared to normal 
and does not achieve enough sustained functional compensation (Shefner et al., 2006; Mancuso et 
al., 2011b). 
Neuregulin-1 (Nrg1) is a neurotrophic factor essential for normal development, as well as 
for maintaining normal function in the mature nervous system (Esper et al., 2006; Stassart et al., 
2012). Nrg1 contributes to axonal regeneration and normal myelination in mice (Stassart et al., 
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2012) through its effects on Schwann cells, whereas silencing of Nrg1 impairs axonal regeneration 
(Fricker et al., 2011). It also plays an important role in NMJ maintenance (Wolpowitz et al., 2000) 
by regulating multiple aspects of Schwann cell differentiation, proliferation, motility, and 
myelination (Esper et al., 2006) and promoting acetylcholine receptor clustering at the NMJ during 
development (Ngo et al., 2012). Nrg1 increases terminal Schwann cells survival after postnatal 
denervation and promotes process extension required for new NMJ formation (Trachtenberg and 
Thompson, 1996; Hayworth et al., 2006). It has been also shown that Nrg1 alterations produce 
severe deficits in the formation and maturation of muscle spindles, thereby compromising the 
proprioceptive sensory system (Cheret et al., 2013). The exact role of Nrg1 type I (thereafter named 
Nrg1-I) on the peripheral nervous system is not fully known. It has been reported that Nrg1-I 
expression by Schwann cells is essential for promoting axonal regeneration and remyelination 
(Stassart et al., 2012). I addition, Nrg1-I administration has been shown to alleviate Charcot-Marie-
Tooth disease in mice (Fledrich et al., 2014). Nrg-1/ErbB system alterations have been related to 
ALS, with reduced Nrg1 type-III expression in ALS patients and SOD1G93A mice (Song et al., 
2012). Loss-of-function mutations on Nrg1 receptor ErbB4 produce late-onset ALS in human 
patients (Takahashi et al., 2013). Because the manipulation of Nrg1 expression might represent a 
promising novel approach to treat ALS, the main goals of the present work were to investigate the 
contribution of the extracellular domain of Nrg1-I in ALS and to test the effect of its overexpression 
at the NMJs in SOD1G93A ALS mice. 
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Material and methods 
Transgenic mice  
SOD1G93A transgenic mice (B6SJL-Tg[SOD1-G93A]1Gur) were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). Hemizygotes B6SJL SOD1G93A males were obtained by 
crossing with B6SJL females from the CBATEG (Bellaterra, Spain). The offspring was identified 
by PCR of DNA extracted from tail tissue. Mice were kept in standard conditions of temperature 
(22±2 °C) and a 12:12 light:dark cycle with access to food and water ad libitum. All experimental 
procedures were approved by the Ethics Committee of the Universitat Autònoma de Barcelona, 
where the animal experiments were performed. The following experimental groups of SOD1G93A 
mice were used in this study: SOD1+AAV-Nrg1-I (n=20, 10 per each sex), SOD1+AAV-GFP 
(n=10, 5 per each sex), SOD1 untreated (n=10, 5 per each sex), wild type littermates+AAV-Nrg1-I 
(n=10) and untreated wild type littermates (n=10). For partial denervation studies, wild type mice 
were distributed in three groups: rhyzotomy+vehicle (n=10), rhyzotomy+AAV-Nrg1-I (n=9), 
rhyzotomy+lapatinbib (n=9). To compensate the experimental groups, we divided the animals 
according to their weight, the results of pre-treatment electrophysiological tests and, in the case of 
SOD1G93A mice, also the litter of origin. All experiments were performed by blinded researchers. 
 
Virus production and injection 
The cDNA sequence of the extracellular domain of Nrg1-I isoform containing a HA-tag was kindly 
provided by G. Corfas (Harvard Medical School, Boston, MA) and cloned between AAV2 ITRs 
under the regulation of the CMV promoter. The woodchuck hepatitis virus responsive element 
(WPRE) was added at 3’ to stabilize mRNA expression. AAV1 viral stocks were produced by the 
Viral Production Unit of UAB (http://sct.uab.cat/upv) as previously described (Trachtenberg and 
Thompson, 1996) by triple transfection into HEK293-AAV cells of the expression plasmid, 
Rep1Cap2 plasmid containing AAV genes (kindly provided by J.M. Wilson, University of 
Pennsylvania, Philadelphia, USA) and pXX6 plasmid containing adenoviral genes (Hayworth et al., 
2006) needed as helper virus. AAV particles were purified by iodixanol gradient. Titration was 
evaluated by picogreen (Invitrogen) quantification and calculated as viral genomes per milliliter 
(vg/ml). Control serotype-matching AAV1 vectors coding mock or GFP were used as control.  
For intramuscular administration, 1x10E11 vg of AAV1-Nrg1-I in a total volume of 20 µl 
were injected in the gastrocnemius muscles bilaterally using a 33G needle connected to a Hamilton 
syringe in isofluorane-anesthetized mice. AAV1-GFP virus was used as control.  
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Partial denervation of hindlimb muscles 
Surgeries were performed in 5 months-old female B6SJL mice under anesthesia with ketamine (100 
mg/ml) and xylazine (10 mg/ml). A small incision was made in the skin of the dorsum above the 
iliac crest to expose the spinal nerves on the right side. Using fine forceps and microscissors, the 
vertebrae were cleared of muscle, a small laminectomy was performed to expose L4 spinal root, and 
the root was cut at postganglionic level. The incision was sutured and the mice allowed recovering 
before being returned to their cages. For the next 15 days, all experimental mice were subject to 
daily checks for assessment of health and mobility. 
 
Drug administration 
Lapatinib ditosylate (lapatinib, Eurodiagnostico) was used to block tyrosine kinase activity of ErbB 
receptors. 50 μg of the drug were injected in the gastrocnemius muscles of the animals immediately 
after the surgery, and daily intraperitoneal injections (50 mg/kg) were given from day 1 post injury 
until the end of the follow up. 
 
Electrophysiological tests 
For motor nerve conduction tests the sciatic nerve was stimulated percutaneously by means of 
single pulses of 20µs duration (Grass S88) delivered through a pair of needle electrodes placed at 
the sciatic notch. The compound muscle action potential (CMAP, M wave) was recorded from 
tibialis anterior, gastrocnemius and plantar interossei muscles with microneedle electrodes (Navarro 
and Udina, 2009; Mancuso et al., 2011b). All potentials were amplified and displayed on a digital 
oscilloscope (Tektronix 450S) and the amplitude from baseline to the maximal negative peak were 
measured. Mice body temperature was kept constant by means of a thermostated heating pad. 
Motor unit number estimation (MUNE) was made using the incremental technique (Shefner 
et al., 2006; Lago et al., 2007; Mancuso et al., 2011b) with the same setting as for motor nerve 
conduction tests. Starting from subthreshold intensity, the sciatic nerve was stimulated with single 
pulses of gradually increasing intensity and quantal increases in the CMAP were recorded. 
Increments >50 µV were considered as the recruitment of an additional motor unit. The mean 
amplitude of a single motor unit was calculated as the average of 15 consistent increases. The 
estimated number of motor units results from the equation: MUNE = CMAP maximal 
amplitude/mean amplitude of single motor unit action potentials. 
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Histology 
Mice were transcardially perfused with 4% paraformaldehyde in PBS and the lumbar spinal cord, 
tibial nerve and gastrocnemius muscles were harvested. For spinal motoneuron evaluation, spinal 
cords were postfixed during 4h, cryopreserved in 30% sucrose in PBS, and 40 μm transverse 
sections cut using a cryotome (Leica) and collected serially in Olmos solution (100mM phosphate 
buffer pH 7.2, 30% sucrose, 1% polyvinylpyrrolidone, 30% ethylene glycol). One every two slides 
of each animal was stained with cresyl violet. Motoneurons were identified by their localization in 
the ventral horn and counted following strict size and morphological criteria: only neurons with 
diameter larger than 20 μm, polygonal shape and prominent nucleoli were counted. For each slide, 
the number of motoneurons present in both ventral horns was counted in four serial sections per 
slide of each L4 and L5 segments determined according to anatomical landmarks (Mancuso et al., 
2011b). We calculated the total number of L4-L5 motoneurons by applying Abercrombie’s 
correction (Abercrombie, 1946). 
For morphological evaluation of axons, the tibial nerve was harvested and post-fixed in 
glutaraldehyde/paraformaldehyde (3%/3%) overnight at 4°C, post-fixed in 2% osmium tetroxide, 
dehydrated, and embedded in epon resin (Electron Microscopy Sciences, Hatfield, PA, USA). 
Transverse semithin sections (0.5 μm thick) were cut with an ultramicrotome (Leica), stained with 
toluidine blue, and examined by light microscopy. 
For muscle immunohistochemistry, the gastrocnemius muscles were cryopreserved in 30% 
sucrose in PBS and 60 μm longitudinal sections were serially cut with a cryotome and collected in 
sequential series of 10 in Olmos solution. Sections were blocked with PBS-0.3%Triton-5% fetal 
bovine serum and incubated 48h at 4°C with primary antibodies anti-synaptophysin (1:500, 
AB130436, Abcam), anti-neurofilament 200 (NF200, 1:1000, AB5539, Millipore), anti-S100β (1:1, 
22520, Immunostar), anti-phospho-ErbB4 (1:100, sc-283, Santa Cruz Biotechnology), anti-
phospho-Akt (1:50, Cell Signaling Technologies) and anti phospho-ERK1/2 (1:50, Cell Signaling 
Technologies). After washes, sections were incubated overnight with Alexa 594-conjugated 
secondary antibody (1:200; Life Science), Alexa 594-conjugated streptavidin (1:500, Life Science) 
and Alexa 488 conjugated α-bungarotoxin (1:200, B-13422, Life Technologies). To further amplify 
p-ErbB4 labeling, tyramide signal amplification (TSA) was applied (1:50, 5 minutes, 
NEL700001KT, Perking Elmer). All confocal images were captured with a scanning confocal 
microscope (LSM 700 Axio Observer, Carl Zeiss 40x/1.3 and 60x/1.4 Oil DIC M27). Maximum 
projections images shown in this study were generated from 0.5-2μm z projections. For NMJ 
analysis, the proportion of fully occupied endplates was determined by classifying each endplate as 
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either fully occupied (when presynaptic terminals overly the endplate) or vacant (no presynaptic 
label in contact with the endplate). At least 4 fields totaling >100 endplates were analyzed per 
muscle. For collateral sprouting quantification, the number of sprouts per endplate was quantified 
by counting the neurofilament-positive projections from the pre-synaptic terminal or pre-terminal 
nodes on confocal z projections. For statistical analysis, we considered both the total number of 
sprouts and the proportion of occupied end plates that were originated form a collateral sprout (% of 
sprouts vs. occupied end plates). 3-D reconstructions were performed with Imaris software v. 8.2.0 
(Bitplane AG) from z-stacks obtained from confocal microscopy. 
 
RNA extraction and real time PCR 
The gastrocnemius muscle was dissected, removed and divided in two parts. For RNA extraction 
1000 µl of Qiazol (Qiagen) were added, and tissue homogenized for 6 minutes with Tyssue Lyser 
LT (Qiagen) at 50 Hz twice. Then, samples were purified with chloroform (Panreac), precipitated 
with isopropanol (Panreac), washed with 70% ethanol and resuspended in 20 µl of RNAse free 
water. The RNA concentration was measured using a NanoDrop ND-1000 (Thermo Scientific). 
One µg of RNA was reverse-transcribed using 10 µmol/l DTT, 200 U M-MuLV reverse 
transcriptase (New England BioLabs, Barcelona, Spain), 10 U RNase Out Ribonuclease Inhibitor 
(Invitrogen), 1 µmol/l oligo(dT), and 1 µmol/l of random hexamers (BioLabs, Beverly, MA, USA). 
The reverse transcription cycle conditions were 25°C for 10 min, 42°C for 1 h and 72°C for 10 min. 
We analyzed the mRNA expression of murine ErbB4 by means of specific primer sets (forward: 
AGATCACCAGCATCGAGCAC, reverse: TGGTCTACATAGACTCCACC). m36B4 expression 
was used to normalize the expression levels of the different genes of interest for mouse samples 
(m36B4 forward: ATGGGTACAAGCGCGTCCTG, reverse: AGCCGCAAATGCAGATGGAT) 
Gene-specific mRNA analysis was performed by SYBR-green real-time PCR using the 
MyiQ5 real-time PCR detection system (Bio-Rad Laboratories, Barcelona, Spain). The thermal 
cycling conditions comprised 5min polymerase activation at 95°C, 45 cycles of 15s at 95ºC, 30s at 
60ºC, 30s at 72ºC and 5s at 65°C to 95°C (increasing 0.5°C every 5s). Fluorescence detection was 
performed at the end of the PCR extension, and melting curves were analyzed by monitoring the 
continuous decrease in fluorescence of the SYBR Green signal. Quantification relative to 36B4 
controls was calculated using the Pfaffl method (Pfaffl, 2001). 
 
Protein extraction and western blot 
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The other part of the gastrocnemius muscle was prepared for protein extraction and homogenized in 
modified RIPA buffer (50 mM Tris–HCl pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.2% SDS, 100 mM NaCl, 1 mM EDTA) adding 10 µl/ml of Protease Inhibitor cocktail (Sigma) 
and PhosphoSTOP phosphatase inhibitor cocktail (Roche). After clearance, protein concentration 
was measured by Lowry assay (Bio-Rad Dc protein assay). 
For Western blots, 20-60 μg of protein of each sample were loaded in SDS-poliacrylamide 
gels. The transfer buffer was 25 mM trizma-base, 192 mM glycine, 20% (v/v) methanol, pH 8.4. 
The membranes were blocked with 5% BSA in PBS plus 0.1% Tween-20 for 1 hour, and then 
incubated with primary antibodies at 4°C overnight. The primary antibodies used were: anti-
Neuregulin 1 (1:200, sc-228916, Santa Cruz Biotechnology), anti-ErbB4 (1:200, sc-283, Santa Cruz 
Biotechnology), anti-Akt (1:200, sc-8312, Santa Cruz Biotechnology), and-pAkt (1:200, sc-7985-R, 
Santa Cruz Biotechnology), anti-ERK1/2 (1:500, 4348, Cell Signaling), anti-pERK1/2 (1:500, 
9106, Cell Signaling), anti-GSK3β (1:500, ab31366, Abcam), anti-pGSK3β(S9) (1:500, ab75814, 
Abcam), anti-GAPDH (1:20000, MAB374, Millipore). Horseradish peroxidase–coupled secondary 
antibody (1:5000, Vector) incubation was performed for 60 min at room temperature. The 
membranes were visualized using enhanced chemiluminiscence method and the images were 
collected and analyzed with Gene Genome apparatus and Gene Snap and Gene Tools software 
(Syngene, Cambridge, UK). 
 
Kinase phosphorylation assay (ELISA) 
The phosphorylation levels of Akt and ERK1/2 was determined by the Phosphotracer ELISA kit 
(ab185432, Abcam) in a semi-quantitative method. We used RIPA homogenized mouse muscle and 
the amount of phosphorylated protein was determined according to the manufacturer instructions. 
 
Human samples processing 
Muscle biopsies were obtained from muscles of ALS patients (supplementary table 1) using an 
open biopsy after subcutaneous anesthesia, and the samples were immediately frozen in liquid 
nitrogen. Written informed consent was obtained from all participants and the research ethics 
committee from the institution approved the study. The biopsy sample from each individual was 
used to obtain RNA and protein extracts.  
The RNA extraction was carried out using TriReagent (Sigma-Aldrich Co). The quality of the 
extracted RNA was checked in the NanoDrop spectrophotometer and 28S as well as 18S rRNA 
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bands were visualized in an agarose gel. The cDNA was obtained from 1 µg of total extracted RNA 
(High Capacity cDNA RT kit; Applied Biosystems). For ErbB4 mRNA expression analysis we 
used specific set of primers for ErbB4 (forward: CTTTAATTACCGCAGCCGCC, reverse: 
AAAGAGGCGGTAGGTTTCCG) and h36B4 for normalization (forward: 
ATGCAGCAGATCCGCATGT; reverse: TTGCGCATCATGGTGTTCTT).  
For protein analysis, muscle biopsies were homogenized in modified RIPA buffer (50 mM 
Tris–HCl pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% SDS, 100 mM NaCl, 1 mM 
EDTA) adding 10 µl/ml of Protease Inhibitor cocktail (Sigma) and PhosphoSTOP phosphatase 
inhibitor cocktail (Roche). After clearance, protein concentration was measured by.BCA assay 
(Pierce). For Western blot, the experimental conditions were the same than those used for the 
analysis of murine samples. The antibody used was anti-ErbB4 (1:200, sc-283, Santa Cruz 
Biotechnology).  
 
Statistics 
All experiments were performed by blinded researchers using randomized animal groups. 
Data are expressed as mean ± SEM. Kolmogorov-Smirnov and Fisher tests were applied in order to 
determine the normality and the homogeneity of variances of data sets, respectively. 
Electrophysiological test results were statistically analyzed using one-way or repeated 
measurements ANOVA, applying Tukey post-hoc test when necessary. Histological and molecular 
biology data were analyzed using ANOVA and Tukey post-hoc, t-Student, or Kruskal-Wallis and 
Mann-Whitney tests. 
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Results 
ErbB4 receptor is localized at the neuromuscular junction and down regulated in SOD1G93A mice 
and ALS patients skeletal muscles 
We first evaluated ErbB4 and ErbB2 expression along disease progression in SOD1G93A muscles by 
real time PCR. We found a significant reduction of ErbB4 mRNA levels that correlates with the 
pattern of muscle denervation (Hegedus et al., 2007). ErbB4 mRNA was decreased from 8 weeks of 
age in gastrocnemius muscle and later, from 12 weeks, in soleus muscle, which is more resistant to 
the disease with delayed onset of denervation (Fig. 1a). Further immunohistochemical evaluation of 
mouse muscles showed that ErbB4 receptors were localized at the neuromuscular junction, being 
likely expressed in the terminal Schwann cells (Fig. 1b, note the co-labeling between ErbB4 and 
DAPI staining). On the contrary, the analysis of ErbB2 receptor in the gastrocnemius muscle 
revealed no changes along disease progression (Fig. 1c). We then analyzed human samples from 
sporadic and familial ALS patients (supplementary table 1) and found significantly decreased 
ErbB4 mRNA and protein levels compared to control values (Fig. 1d). Remarkably, ErbB4 protein 
levels were below 50% of normal expression in muscles of all ALS patients (Fig. 1d, right panel). 
This finding is in agreement with previous reports of loss-of-function ErbB4 mutations as causative 
of late-onset ALS (Takahashi et al., 2013).  
 
AAV-Nrg1-I intramuscular injection promotes functional compensation by enhancing collateral 
sprouting in SOD1G93A muscle. 
In order to assess the role of Nrg1/ErbB pathway, we used a gene therapy strategy based on the 
bilateral intramuscular injection of 1 x 1011 viral genomes of an adeno-associated viral vector 
(AAV) encoding for soluble Nrg1-I (or GFP as a control) into SOD1G93A gastrocnemius muscles 
previous to the clinical disease onset (at 8 weeks of age) (Fig. 2a and b). We first evaluated the 
GFP expression pattern in the muscles to determine which structures were transfected with the 
AAV and thereby expressed the transgene. We found that a high proportion of muscle fibers, but 
not axons or Schwann cells, were positive for GFP staining. In addition, we controlled the potential 
detrimental effect of the AAV-injection per se by functionally evaluating the effect of AAV-GFP 
intramuscular injection in SOD1G93A mice, and found no alterations derived by the virus injection in 
the outcome of the animals (Supplementary fig. 1).  
Induced Nrg1-I expression was confirmed in the animals at the time of sacrifice (16 weeks), 
showing significantly higher levels of Nrg1-I in the gastrocnemius muscles injected compared to 
untreated wild type and SOD1G93A mice (Fig. 2c). The functional effect of AAV-Nrg1-I injection 
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was evaluated in the hindlimb muscles of SOD1G93A mice by means of electrophysiological tests, 
which have been demonstrated to reliably monitor disease progression in ALS patients and animal 
models (Azzouz et al., 1997; Shefner et al., 2006; Mancuso et al., 2011b). Results revealed a 
selective preservation of the gastrocnemius compound muscle action potential (CMAP) from 10 
weeks of age, without affecting adjacent non-injected muscles, such as the tibialis anterior muscle 
(Fig. 2d). The preserved CMAP amplitude might result from increasing either the number or the 
size of motor units by collateral sprouting, a compensatory mechanism by which intact 
motoneurons expand to reinnervate denervated endplates on muscle fibers (Tam and Gordon, 
2003b). We estimated the size and number of motor units by the incremental technique and found 
that Nrg1-I overexpression had no effect regarding the number of motor units, but significantly 
increased motor unit mean amplitude. The frequency distribution of motor units grouped by 
amplitude of the action potential revealed a clear shift to the right in the Nrg1-I treated animals, 
corroborating the increased size of motor units (Fig. 2e). Further histological analysis confirmed 
these findings since the treatment had effect neither on total motoneuron preservation at L4-L5 
spinal segments nor on myelinated axons at the tibial nerve (Fig. 2f, top and middle panels), but 
higher number of occupied motor endplates were observed in the gastrocnemius muscle after AAV-
Nrg1-I injection compared to untreated SOD1G93A mice (Fig. 2f, bottom panel). We also observed 
an increased proportion of occupied endplates by terminal and nodal collateral sprouts and a higher 
number of sprouting profiles in treated muscles (Fig. 2g). The enhanced collateral sprouting in 
Nrg1-I treated muscles was confirmed by the presence of terminal Schwann cells extending 
processes to neighbor end plates (Fig. 2h), which have been shown to be essential for the guidance 
of new axonal sprouts (Kang et al., 2014). 
These findings confirm the hypothesis of Nrg1-I increasing the number of neuromuscular 
connections by promoting collateral sprouting and reinnervation. Nevertheless, the increased 
functionality of just the gastrocnemius muscles was not enough for improving the global disease 
outcome of the animals, evidenced by the lack of differences in the rotarod performance or the 
clinical disease onset (Fig. 3). 
To better mimic a clinical situation, we studied another group of SOD1G93A mice injected 
with AAV-Nrg1-I at 12 weeks of age, the usual time of clinical onset of the disease in this model 
(Ripps et al., 1995; Mancuso et al., 2011a; 2011b). Results revealed also significant preservation of 
gastrocnemius CMAP amplitude, accompanied by increased size of motor units potential amplitude 
and a higher percentage of occupied endplates (Fig. 4), thereby confirming the beneficial effect of 
Nrg1-I overexpression even when applied at a stage of higher degree of muscle denervation. 
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AAV-Nrg1-I effect is mediated by the activation of Akt and ERK1/2 dependent pathways 
We next analyzed the signaling pathways underlying the effect observed upon Nrg1-I 
overexpression in SOD1G93A mice muscles. We found increased ErbB4 protein levels in AAV-Nrg1-
I injected mice at 16 weeks, together with an increased phosphorylation of the receptor in terminal 
Schwann cells at the neuromuscular junction (Fig. 5a and b). We performed orthogonal views from 
confocal microscopy z-stacks and 3D reconstructions in order to confirm ErbB4 localization, and 
found that it is present in the surface of terminal Schwann cells, indicating that these cells are the 
main target of the enforced Nrg1-1 expression (Fig. 5c and d). To corroborate the functional 
activation of ErbB receptors through Nrg1 signaling we analyzed changes in the phosphorylation 
levels of Akt, ERK1/2, and GSK3β, members of the MAPK family known to be downstream of 
ErbB (Mei and Xiong, 2008; Fledrich et al., 2014). We found activation of both Akt and ERK1/2, 
evidenced by the relative higher phosphorylated form compared to total protein in AAV-Nrg1-I 
injected muscles (Fig. 5e, g and i). Interestingly, further immunohistochemical analysis revealed a 
restricted activation of ERK1/2 co-localizing with the motor endplate, and Akt in skeletal muscle 
fibers (Fig. 5f and h). In addition, the enhanced Akt activation was confirmed by the inhibition of 
GSK3β, as indicated by the increased inhibitory S9 specific phosphorylation (Fig. 5i). Such Akt-
dependent beneficial effect was recently reported for soluble Nrg1-I on Schwann cells in a Charcot-
Marie-Tooth 1A rat model (Fledrich et al., 2014). 
 
Nrg1/ErbB signaling pathway plays a crucial role in motor collateral sprouting 
To further understand the role of Nrg1 on axonal collateral sprouting, we used a model of hindlimb 
muscle partial denervation, consisting in postganglionic axotomy of the L4 spinal nerve 
(rhyzotomy) in wild type mice (Gordon et al., 2010) (Fig. 6a). ErbB4 receptor mRNA levels in 
partially and completely denervated muscles were significantly reduced after 3 days compared to 
naive animals (Fig. 6b). We histologically and functionally characterized the effect of the L4 
rhyzotomy. Tibial nerve histology at 15 days revealed a significant decrease of approximately 30% 
of myelinated axons (Fig. 6c). Electrophysiological tests showed that tibialis anterior and 
gastrocnemius CMAPs dropped to 65 and 55% and progressively recovered to 90 and 95% of naive 
values, respectively (Fig. 6d), although there were no clear functional alterations in behavior (data 
not shown). These data correlates with previous studies showing similar percentages of muscle 
innervation after selective L4/L5 avulsion in male mice (Gordon et al., 2012). Therefore, this model 
allows consistent partial denervation of selected muscles and fast recovery of neuromuscular 
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function due to collateral reinnervation. Next, we studied three rhyzotomy experimental groups 
intramuscularly injected with 1x1011 vg of AAV1-Nrg1-I (14 days prior to injury), with lapatinib 
(an ErbB receptor tyrosine kinase activity inhibitor) or with vehicle (Fig. 7a). Results revealed that 
Nrg1-I overexpression enhanced the recovery of gastrocnemius CMAP by accelerating collateral 
reinnervation, but without altering the maximum compensatory enlargement of each motor unit, 
evidenced by the lack of differences in the mean motor unit potential amplitude at late time points. 
On the contrary, ErbB inhibition by lapatinib completely blocked functional recovery of 
gastrocnemius muscle CMAP by inhibiting collateral sprouting and the increase of motor units size 
(Fig. 7a and b). Histological analysis at 15 days after rhyzotomy confirmed these results since 
lapatinib-treated animals showed reduced percentage of occupied muscle endplates and few 
collateral sprouts. In addition, the lack of histological differences between Nrg1-I and vehicle 
groups confirms that Nrg1-I accelerates collateral sprouting rather than increases the maximum 
motor unit compensatory capacity (Fig. 7c and d). Although Nrg-1-I has been already related to 
peripheral nerve regeneration mainly by its actions on Schwann cells (Stassart et al., 2012), this is 
the first report demonstrating an important role of Nrg1-I in the collateral sprouting process. A note 
of caution might be taken for lapatinib treatment, since this drug is not specific for ErbB4 receptors 
and the observed effect may be explained in part by blocking of other ErbB receptor subtypes. 
 
Nrg1 effect on collateral sprouting is also dependent on the activation of Akt and ERK1/2. 
We further analyzed Nrg1-I and ErbB4 expression levels and activation of MAPK signaling 
pathways in the rhyzotomy model. As expected, Nrg1-I levels increased in the muscles injected 
with AAV-Nrg1-I. Surprisingly, we also found slight increase of endogenous Nrg1-I after 
rhyzotomy in vehicle-injected muscles that was reduced by lapatinib. We did not find differences in 
ErbB4 expression after AAV-Nrg1-I administration, but ErbB4 levels were markedly reduced by 
lapatinib treatment, probably due to the lower levels of muscle innervation in this case. MAPK 
analyses revealed no significant effect of Nrg1-I overexpression in terms of Akt and ERK1/2 
phosphorylation after rhyzotomy. In contrast, lapatinib administration led to a dramatic decrease of 
both Akt and ERK1/2 activity (Fig. 7e).  
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Discussion 
It was recently reported that loss-of-function mutations on the Nrg1 receptor ErbB4 produce 
a form of late-onset, autosomal-dominant ALS in humans (Takahashi et al., 2013), opening a new 
field for searching novel therapeutic approaches. Thereby, the main goal of the present work was to 
determine the role of soluble Nrg1-I in ALS by assessing the effect of its overexpression at the 
NMJs in SOD1G93A mice. Our novel results show that Nrg1-I plays an important role for collateral 
sprouting of motor axons and reinnervation of partially denervated muscles, and that overexpression 
of Nrg1-I by an AAV vector promotes functional compensation in SOD1G93A mouse muscles by 
enhancing collateral reinnervation. 
ALS is a multifactorial disease in which a complex network of pathophysiological processes 
results in the progressive degeneration of motoneurons (Mancuso and Navarro, 2015). Many efforts 
are directed to therapeutically target one or more of these pathophysiological events in order slow-
down ALS disease progression (Mancuso and Navarro, 2015). Motoneuron death is preceded by 
failure of NMJs and axonal retraction (Fischer et al., 2004; Mancuso et al., 2011b), which seem 
dependent upon alterations in the interaction of motor axons with accompanying terminal Schwann 
cells and skeletal muscle fibers. Importantly, we show for the first time that Nrg1-I overexpression 
in SOD1G93A mice produced significant functional compensation by enhancing collateral sprouting 
by acting on terminal Schwann cells, thus inducing active functional recovery rather than 
preservation of motoneurons. 
Many efforts have been conducted to elucidate the role of Nrg1 in the peripheral nervous 
system. However, most of them were mainly focused on the Nrg1 type III (Nrg1-III) (Esper et al., 
2006; Nave and Salzer, 2006; Mei and Xiong, 2008). It has been shown that Nrg1-III enhances 
remyelination and regeneration by stimulating Schwann cells migration after nerve injury in the 
adulthood (Fricker et al., 2011; Wakatsuki et al., 2013). Moreover, it has been suggested that this 
effect was dependent upon endogenous BDNF signaling through axonal trkB receptors, which 
promote a stage-dependent release of Nrg1-III from axons to Schwann cells (Ma et al., 2011). 
Nrg1-III has been also reported to have an important effect on central nervous system myelination 
by inducing the proliferation of oligodendrocyte precursors (Ortega et al., 2012) and even 
oligodendrocyte replacement and maintenance after spinal cord injury, leading to improved 
functional outcome (Gauthier et al., 2013).  
Despite the important role of Nrg1-III on peripheral nervous system development and 
regeneration after traumatic injuries, the exact role of Nrg1-I on the peripheral nervous system is 
not fully known. Recent findings suggest that it also contributes to axonal maintenance and 
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regeneration. Cheret et al. (Cheret et al., 2013) recently showed that Nrg1 alterations produce 
severe deficits in the formation and maturation of muscle spindles, thereby compromising the 
proprioceptive sensory system. After nerve injury, Schwann cell detachment from axons triggers 
Nrg1-I expression that is essential for promoting axonal regeneration and remyelination (Stassart et 
al., 2012). Interestingly, Nrg1-I induces Schwann cells proliferation after peripheral nerve injury 
through ERK activation (Lee et al., 2014). Most importantly, beneficial effects of Nrg1-I 
administration have been recently observed in a rodent model of Charcot-Marie-Tooth disease, in 
which axonal Nrg1-I overexpression drives Schwann cells towards differentiation and preserves 
peripheral axons through PI3K-Akt signaling (Fledrich et al., 2014). We provide the first evidence 
of the role of Nrg1-I in collateral sprouting on partially denervated muscles. We showed how Nrg1-
I is able to activate ErbB4 receptors present in terminal Schwann cells at the neuromuscular 
junction, and induce active collateral reinervation. Chronic blockade of ErbB receptors abolishes 
this process. Our present results on the critical role of Nrg1-I in the process of motor axon collateral 
sprouting and reinnervation of vacant NMJ are in agreement with previous findings reporting Nrg1-
I effect on Schwann cells through the activation of MAPK pathways (Fledrich et al., 2014). In this 
sense, Nrg1-I has been shown to be also critical for the stability of AChRs at the NMJ and the 
structural integrity of the postsynaptic apparatus (Schmidt et al., 2011). Interestingly, knockdown of 
axonally-derived Nrg1-III produced severe impairment of remyelination after sciatic nerve crush, 
together with excessive terminal sprouting observed at the NMJ level (Wolpowitz et al., 2000). 
These findings might suggest an opposite action of Nrg1-I and Nrg1-III in terms of modulating 
motor axonal sprouting. However, the excess terminal sprouting after Nrg1-III silencing might be a 
compensatory reaction to the grossly impaired remyelination of the motor axons rather than a direct 
consequence of the absence of Nrg1-III at the NMJ. Indeed, increased NMJ terminal sprouting has 
been also described in a transgenic mouse model of demyelinating neuropathy as a consequence of 
demyelination and conduction block (Baloh et al., 2009). 
Although the molecular mechanisms underlying collateral sprouting are still unknown, the 
cellular events taking place in the process have been well studied. Terminal Schwann cells in 
denervated NMJ are able to extend processes and migrate towards neighbor occupied end plates. 
Then, growing collateral and terminal sprouts from preserved motor axons follow these Schwann 
cell processes to reinnervate the vacant end plates (Tam and Gordon, 2003b; Harrisingh et al., 2004; 
Kang and Thompson, 2003; Kang et al., 2014). Remarkably, we observed that phospho-ErbB4 
expression is located at the surface of terminal Schwann cells upon Nrg1-I enforced expression in 
the muscles (see figure 5b). Our results demonstrate that Nrg1-I acts on terminal Schwann cells, 
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likely enhancing its role as bridges for the collateral reinnervation of muscle fibers. The induction 
of a constitutively active receptor ErbB2 in Schwann cells, simulating continuous neuregulin 
signaling to these cells, was reported to lead to changes in terminal Schwann cells that mimiked the 
response to muscle denervation/reinnervation (Hayworth et al., 2006). This activation of Schwann 
cells resulted in the sprouting of nerve terminals following the extensions of the terminal Schwann 
cells. 
 Our results also reveal an activation of ERK1/2 in motor endplates of Nrg1-I treated 
muscles. In this sense, it has been shown that ERK is crucial for the events occurring in Schwann 
cells after peripheral nerve injury, including proliferation, migration and remyelination. Following 
nerve injury, Schwann cells respond to axonal damage with a strong, sustained activation of the 
ERK signaling pathway (Harrisingh et al., 2004). In addition, sustained Raf/MEK/ERK signaling 
triggered in Schwann cells is able to switch their condition into a proliferative, remyelinating state 
even when interacting with intact axons (Napoli et al., 2012). Overall, our findings suggest that 
Nrg1-I overexpression is able to enhance collateral reinnervation of empty motor endplates by 
acting on terminal Schwann cells in an ERK1/2 dependent manner. 
 A note of caution might be taken regarding the lack of global effects observed in the 
functional outcome of Nrg1-I treated ALS mice. It is unlikely that Nrg1-I enforcement in single 
muscles would globally affect ALS disease progression, but we believe that our findings of 
increased collateral reinnervation in SOD1G93A mice with enhanced Nrg1-I expression represents a 
crucial step forward the development of new therapies for motoneuron disease. In this sense, our 
work constitutes a convincing proof of concept that establishes the basis for investigating the 
therapeutic impact of Nrg1-I widespread expression in ALS models. 
In conclusion, the present results demonstrate an important role of Nrg1-I on axonal 
sprouting and muscle collateral reinnervation. Nrg1-I overexpression in SOD1G93A mice produced 
significant functional compensation by promoting collateral reinnervation, thereby opening a new 
window for developing new therapies focusing on functional recovery rather than preservation for 
motoneuron diseases. 
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Figure legends  
 
Figure 1. ErbB4 expression in muscles from SOD1G93A mice and ALS patients. (a) Real time 
PCR analysis of ErbB4 mRNA in SOD1G93A mice showed downregulation with a different pattern 
depending upon the analyzed muscle. The gastrocnemius muscle (GCm) showed marked ErbB4 
mRNA reduction from 8 weeks of age, whereas the more ALS-resistant soleus muscle showed 
ErbB4 mRNA reduction from 12 weeks of age (n=3 animals per group and time point, ANOVA 
**p<0.01 vs. control). (b) Representative confocal images of ErbB4 expression at the 
neuromuscular junction in the mouse. The observed pattern of expression points to a terminal 
Schwann cell localization (scale bar = 10μm). (c) ErbB2 mRNA expression showing no differences 
along disease progression in gastrocnemius muscle of SOD1G93A mice. (d) Real time PCR from 
samples of patients affected by sporadic or familial ALS showed reduced ErbB4 mRNA levels 
compared to control subjects, consistent with a severe reduction of ErbB4 protein levels (t-Student 
test, *p<0.05; ***p<0.001 vs. control). Numbers in parentheses indicate the number of tissue 
samples analyzed. Values are represented as mean±SEM. Individual levels of ErbB4 protein in each 
ALS patient are shown in the right panel. Additional information about patients features is provided 
in the supplementary table 1.  
 
Figure 2. Effect of intramuscular AAV-Nrg1-I injection in SOD1G93A mice. (a) Expression 
cassette and (b) representation of the administration procedure in the gastrocnemius muscle. (c) 
Nrg1-I protein levels were largely increased in the AAV-Nrg1-I injected muscles (n=10 animals per 
group with balanced sexes; one-way ANOVA, ***p<0.001 vs. wild type (wt) and SOD1G93A 
untreated mice (SOD1c). (d) Electrophysiological tests revealed that AAV-Nrg1-I injection 
produced preservation of the amplitude of gastrocnemius CMAP in treated animals from 10 weeks 
of age (n= 20 animals per group, balanced sexes; repeated measurements ANOVA, **p<0.01; 
***p<0.001 vs. SOD1 untreated mice). In contrast there were no differences between treated and 
control SOD1 mice in the amplitude of CMAP recorded in the tibialis anterior muscle (non-
injected) along time. (e) Electrophysiological estimation of motor unit number (MUNE) and mean 
amplitude of single motor unit potential (SMUA) of the gastrocnemius muscle revealed that the 
increased CMAP amplitude was the result of increased size of motor units (t-Student test, 
***p<0.001 vs. SOD1 untreated mice). This was confirmed by the shift to the left in the frequency 
distribution plot of motor unit potential amplitude in the animals treated with AAV-Nrg1-I (Chi-
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square test, p<0.05). (f) Histological analysis showed similar loss in the number of motoneurons in 
the ventral horn of the spinal cord (Nissl staining; top panels, scale bar = 250μm), and in the 
number of myelinated fibers of the tibial nerve (semithin sections stained with toluidine blue; mid 
panels, scale bar = 10μm) in treated and untreated SOD1G93A mice. Immunohistochemical labeling 
for axons (NF-200 and synaptophysin) and end plates (α-bungarotoxin) of the gastrocnemius 
muscle of 16 weeks-old SOD1G93A mice revealed a significantly increased number of occupied 
motor endplates after AAV-Nrg1-I injection (n=10 animals per group, balanced sexes; one-way 
ANOVA, **p<0.01 vs. wild type; ##p<0.01 vs. untreated SOD1 mice; scale bar = 250μm). (g) 
Representative images of nodal and terminal sprouts (pointed by arrowheads) from motor axons in 
the gastrocnemius muscle of SOD1G93A mice injected with AAV-Nrg1-I (scale bar = 15μm). Higher 
numbers of terminal and nodal collateral sprouts were counted in SOD1G93A mice treated with 
AAV-Nrg1-I than in untreated SOD1G93A mice (t-Student test, **p<0.01 vs. untreated SOD1 mice). 
(h) Representative confocal microphotographs of terminal Schwann cells (S100) extending 
processes to connect motor endplates in AAV-Nrg1-I injected muscles. Arrowheads point to 
terminal Schwann cell bodies (scale bar = 15μm). For all graphs, values are mean±SEM. 
 
Figure 3. Effect of Nrg1-I overexpression on functional outcome of SOD1G93A mice. Enhanced 
expression of Nrg1-I exclussively localized in the gastrocnemius muscle was not able to improve 
the global functional outcome of the animals neither in (a) the rotarod nor in (b) the clinical disease 
onset. 
 
Figure 4. AAV-Nrg1-I injection in SOD1G93A gastrocnemius muscle at 12 weeks of age. (a) 
AAV-Nrg1-I injection at 12 weeks of age promotes slight but significant increase in the 
gastrocnemius muscle compound action potential (CMAP) (n= 8 treated vs. 20 untreated animals; 
repeated measures ANOVA, *p<0.05 vs. SOD1 untreated mice), accompanied by an increase in the 
single motor unit potential amplitude (SMUA) (t-Student test). (b) Immunohistochemical labeling 
of axons and endplates of the gastrocnemius muscle showed increased proportion of occupied 
endplates after the Nrg1-I treatment (n= 8 treated vs. 10 untreated animals; t-Student test). Values 
are mean±SEM. 
 
Figure 5. Nrg1-I enforced expression targets terminal Schwann cells in SOD1G93A mice 
gastrocnemius muscle. (a) Western blot analysis indicated partially recovered ErbB4 expression 
after Nrg1-I treatment (n=10 animals per group, balanced sexes). (b) Representative confocal 
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images showing pErbB4 expression in terminal Schwann cells of Nrg1-I treated animals. Scale bar 
= 10μm. (c) Orthogonal views confirmed the co-localization of pErbB4 in terminal Schwann cells, 
and (d) 3-D reconstructions from confocal z-stacks showed pErbB4 in the plasma membrane of 
these cells. Scale bar = 10μm. (e) Western blot of muscle samples revealed a significant activation 
of ERK1/2 after Nrg1-I overexpression, whereas (f) further IHC analysis revealed restricted 
ERK1/2 phosphorylation in the neuromuscular junction of treated animals, with a pattern of 
staining consistent with Schwann cells localization and morphology. (g) Western blot of muscle 
samples revealed a significant activation Akt after Nrg1-I overexpression, whereas (h) further IHC 
analysis revealed restricted Akt phosphorylation in skeletal muscle fibers. (i) Increased activation of 
ERK1/2 and Akt in Nrg1-I treated muscles was confirmed by ELISA, and by the phosphorylation 
of GSK3β. Scale bars are 10μm. Values are mean±SEM. For all plots, one-way ANOVA test, # 
p<0.05 vs. untreated wild type; * p<0.05 vs. untreated SOD1G93A mice. 
 
Figure 6. L4 rhyzotomy model characterization. (a) Representation of the postganglionic L4 
rhyzotomy. (b) ErbB4 mRNA levels were downregulated at 5 days post injury in gastrocnemius 
muscle after partial (L4 rhyzotomy) and total (sciatic nerve cut) denervation (n=4-5 animals per 
group, ANOVA, **p<0.05 vs. naive mice). (c) Tibial nerve histology revealed approximately 30% 
loss of myelinated axons (n=4-5 animals per group, t-Student test, *p<0.05 vs. naive mice, scale bar 
= 10 μm). (d) Compound muscle action potential (CMAP) recordings showed no alteration of 
plantar muscles (innervated by L5-L6 ventral roots), but a marked drop to 65 and 55% of normal 
values for tibialis anterior and gastrocnemius muscles (innervated by L4-L5 ventral roots) that 
progressively recovered until reaching 90 and 95%, respectively (n=10). 
 
Figure 7. Nrg1-I/ErbB signaling plays a role in collateral sprouting of motor axons. (a) The 
amplitude of the CMAP of the partially denervated gastrocnemius muscle recovered to normal 
values in AAV-Nrg1-I injected mice faster than in vehicle-injected mice, indicating acceleration of 
the collateral reinnervation. In contrast, lapatinib (ErbB inhibitor) injection completely prevented 
collateral reinnervation (n = 10 vehicle, 9 AAV-Nrg1-I and 8 lapatinib administered mice; One-way 
ANOVA, *p<0.05, ***p<0.001 AAV-Nrg1-I vs. vehicle treated animals; ###p<0.001 AAV-Nrg1-I 
vs. lapatinib treated animals; @@@p<0.001 lapatinib vs. vehicle treated animals). (b) The 
amplitude of single motor unit potentials (SMUA) of the gastrocnemius muscle was similarly 
increased in vehicle and AAV-Nrg1-I injected mice, but remained lower in lapatinib injected mice, 
indicating that ErbB blocking prevented collateral reinnervation (*p<0.05, ***p<0.001 between 
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indicated groups) AAV-Nrg1-I was injected in the gastrocnemius muscle of wild type mice 14 days 
prior to the injury for ensuring the maximum Nrg1-I expression. (c) The proportion of occupied end 
plates and of collateral sprouts at 15 days after rhyzotomy was similar in AAV-Nrg1-I and vehicle 
injected muscles, whereas lapatinib injected muscles had lower proportion of innervated endplates 
(***p<0.001). (d) The percentage of endplates occupied by collateral sprouts and the number of 
collateral sprouts counted in the gastrocnemius muscle after rhyzotomy were similar to control mice 
in mice injected AAV-Nfg1-I and significantly reduced in lapatinib injected mice (***p<0.001 
between indicated groups). (e) Molecular profile after AAV-Nrg1-I and lapatinib administration. 
Nrg1-I protein was increased in AAV-Nrg1-I injected animals, whereas lapatinib treatment 
produced a dramatic reduction in the endogenous Nrg1-I and ErbB4 receptor expression, 
accompanied by an inactivation of Akt and ERK1/2 signaling pathways (One-way ANOVA, 
**p<0.01 vs. naive; ##p<0.01 vs. vehicle). For all graphs, values are mean±SEM. 
 
Supplementary figure 1. Effect of AAV-GFP injection in SOD1G93A mice. (a) Confocal images 
showing a high number of muscle fibers transduced by the virus and expressing GFP (scale bar = 
100μm). Arrows and arrowheads show transfected and not transfected muscle fibers, respectively. 
Note the high ratio of GFP positive transfected muscles fibers.  AAV-GFP injection did not produce 
any alteration of the functional outcome in SOD1G93A mice, assessed by (b) rotarod performance 
(values are mean±SEM), (c) clinical disease onset, and (d) gastrocnemius muscle compound muscle 
action potential (CMAP, values are mean±SEM). 
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Fig. 4 
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Fig. 5 
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Fig. 7 
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